Pilot Study of Velcade® in IgA Nephropathy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01103778|
Recruitment Status : Completed
First Posted : April 15, 2010
Last Update Posted : May 1, 2018
The primary objective of this study is to investigate the ability of Velcade® (bortezomib) to induce complete or partial remission in patients with severe IgA nephropathy.
The secondary objectives are to assess clinical outcomes relating to safety and efficacy, such as infection, malignancy, preservation of renal function, partial responders, relapse rate, and to study mechanistic assays to predict remission.
|Condition or disease||Intervention/treatment||Phase|
|Chronic Kidney Disease IgA Nephropathy||Drug: Bortezomib (Velcade®)||Phase 4|
This exploratory single center, open-label, single treatment group assignment, safety and efficacy study will enroll 15 patients with severe IgA nephropathy. Subjects will receive 1 cycle of Velcade® to induce clinical remission. Follow-up visits will occur monthly for a year.
For this pilot study, the proportion of patients with clinical remission or partial response will be analyzed.
Monetary compensation will be provided to study participants.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||11 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Velcade Therapy for Severe IgA Nephropathy|
|Study Start Date :||July 2010|
|Actual Primary Completion Date :||April 17, 2017|
|Actual Study Completion Date :||April 17, 2017|
Experimental: Velcade® therapy
Patients with greater than 1gm of proteinuria per day will receive Velcade®.
Drug: Bortezomib (Velcade®)
Velcade® at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle). A second cycle is to be given a month later for non-responders.
- Proteinuria [ Time Frame: 1 year ]Quantification of urinary protein will be made after treatment by measuring 24 hr urine protein.
- Serum creatinine [ Time Frame: 1 year ]Preservation of renal function will be assessed.
- Laboratory safety assessment and clinical signs of infection [ Time Frame: 1 year ]Complete blood count will be checked at regular intervals to monitor for anemia; liver panel; serum immunoglobulin profile will also be followed
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01103778
|United States, New York|
|The Rogosin Institute|
|New York, New York, United States, 10021|
|Principal Investigator:||Choli Hartono, MD||The Rogosin Institute|